The medical community is buzzing about retatrutide, a new dual GIP and GLP-1 agonist that’s showing remarkable promise in {weight loss trials. Early findings from the SURPASS-2 study demonstrate that this treatment https://mediajx.com/story28767251/retatrutide-the-new-weight-reduction-hope